OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) promotes osteogenic differentiation of mesenchymal stem cells mediated by LncRNA AK141205-induced upregulation of CXCL13
-
Add time:09/01/2019 Source:sciencedirect.com
The aim of present study was to characterize long non-coding RNA (lncRNA) AK141205 as a cellular regulator of osteogenic differentiation of mice mesenchymal stem cells (MSCs) towards OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) (OGP) stimulation. Mice MSCs cells were isolated, transfected with si-AK141205, pcDNA-AK141205 or control, and stimulated with OGP. The AK141205, CXC chemokine ligand-13 (CXCL13), and osteogenic differentiation-associated parameters were determined by western blotting or quantitative RT-PCR. To determine the role of AK141205/CXCL13 in SMCs osteogenic differentiation, SMCs subjected to co-transfection of pcDNA-AK141205 and si-CXCL13 or si-AK141205 and pcDNA-CXCL13, and were submitted for osteogenic differentiation-associated parameters analyses. The results showed that stimulation of SMCs with OGP induced upregulation of both AK141205 and CXCL13, and osteogenic differentiation of MSCs. Transfection of si-AK141205 partly suppressed OGP-induced formation of calcium salt nodules, alkaline phosphatase (ALP) activity and osteogenic differentiation-associated gene expression, suggesting key regulatory role of AK141205. Analysis of CXCL13 expression in SMCspcDNA−AK141205 revealed that AK141205 positively promoted CXCL13 expression via acetylation of H4 histone in the promoter region. This signal transduction was demonstrated to be essential for OGP-induced osteogenic differentiation of MSCs through osteogenic differentiation analysis in simultaneously AK141205/CXCL13 controlled SMCs. In summary, we report a completely novel role of AK141205/CXCL13 as a regulator of OGP-induced osteogenic differentiation of SMCs. Our finding provides a potential therapeutic targeting of AK141205 for enhancing disease-treatment effect of SMCs.
We also recommend Trading Suppliers and Manufacturers of OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3). Pls Click Website Link as below: cas 132996-61-3 suppliers
Prev:Nanocellulose-collagen-apatite composite associated with OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) for bone regeneration
Next:Characterization and in vitro biological evaluation of mineral/OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) nanocomposites synthesized biomimetically on titanium) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Peptide TQS169 prevents osteoporosis in rats by enhancing osteogenic differentiation and calcium absorption09/07/2019
- Resorbable, amino acid-based poly(ester urea)s crosslinked with OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) with enhanced mechanical properties and bioactivity09/06/2019
- Nanostructured materials based on mesoporous silica and mesoporous silica/apatite as OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) carriers09/05/2019
- Novel OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) C-terminal pentapeptide grafted poly(d,l-lactic acid) improves the proliferation and differentiation of osteoblasts: The potential bone regenerative biomaterial09/04/2019
- Fibroin/peptide co-functionalized calcium titanate nanorods improve osteoinductivity of titanium via mimicking osteogenic niche09/03/2019
- Characterization and in vitro biological evaluation of mineral/OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) nanocomposites synthesized biomimetically on titanium09/02/2019
- Nanocellulose-collagen-apatite composite associated with OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) for bone regeneration08/31/2019
- Surface modification of TiO2 nanotubes with OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) to enhance osteoblast differentiation08/30/2019
- Three-dimensional printing and in vitro evaluation of poly(3-hydroxybutyrate) scaffolds functionalized with OSTEOGENIC GROWTH PEPTIDE (cas 132996-61-3) for tissue engineering08/29/2019


